UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 133

Sortiert nach

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical cancer research, 2021-08, Vol.27 (15), p.4160-4167

2021

Volltextzugriff (PDF)

Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas

Investigational new drugs, 2022-08, Vol.40 (4), p.868-869

2022

Volltextzugriff (PDF)

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review

Reviews in endocrine & metabolic disorders, 2021-12, Vol.22 (4), p.1121-1136

2021

Volltextzugriff (PDF)

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study

Clinical cancer research, 2018-03, Vol.24 (5), p.1030-1037

2018

Volltextzugriff (PDF)

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer

Cancer letters, 2017-10, Vol.405, p.100-110

2017

Volltextzugriff (PDF)

Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas

Biomedicine & pharmacotherapy, 2024-07, Vol.176, p.116895, Article 116895

2024

Volltextzugriff (PDF)

The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium

Cancer science, 2021-03, Vol.112 (3), p.1095-1104

2021

Volltextzugriff (PDF)

Reflecting on COVID-19: The Hong Kong Experience of Flattening the Curve Without Lockdown

Journal of Immunotherapy and Precision Oncology, 2020-08, Vol.3 (3), p.105-107

Loong, Herbert H

2020

Volltextzugriff (PDF)

Developing Drugs for Sarcomas in a Brave New World

Journal of Immunotherapy and Precision Oncology, 2020-05, Vol.3 (2), p.62-63

Loong, Herbert H

2020

Volltextzugriff (PDF)

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer

Current treatment options in oncology, 2018-11, Vol.19 (11), p.58-13, Article 58

2018

Volltextzugriff (PDF)

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (7), p.897-906

2018

Volltextzugriff (PDF)

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Current oncology (Toronto), 2022-03, Vol.29 (3), p.2154-2164

2022

Volltextzugriff (PDF)

NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours

Annals of surgical oncology, 2023-05, Vol.30 (5), p.2570-2573

2023

Volltextzugriff (PDF)

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy

BMC women's health, 2017-07, Vol.17 (1), p.55-11, Article 55

2017

Volltextzugriff (PDF)

Primary cardiac sarcomas: A multi‐national retrospective review

Cancer medicine (Malden, MA), 2019-01, Vol.8 (1), p.104-110

2019

Volltextzugriff (PDF)

Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas

ESMO open, 2018-01, Vol.3 (Suppl 1), p.e000293-e000293, Article e000293

2018

Volltextzugriff (PDF)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Cost effectiveness and resource allocation, 2020-11, Vol.18 (1), p.1-9, Article 50

2020

Volltextzugriff (PDF)

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

JTO clinical and research reports, 2022-03, Vol.3 (3), p.100290, Article 100290

2022

Volltextzugriff (PDF)

Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

Cancer, 2015-08, Vol.121 (16), p.2720-2729

2015

Volltextzugriff (PDF)

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial

Journal of clinical oncology, 2018-11, Vol.36 (31), p.JCO2018777847-3100

2018

Volltextzugriff (PDF)

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Cost effectiveness and resource allocation, 2020-01, Vol.18 (1), p.2-14, Article 2

2020

Volltextzugriff (PDF)

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

The New England journal of medicine, 2023-11, Vol.389 (20), p.1839-1850

2023

Volltextzugriff (PDF)

Update on the Management and Therapeutic Monitoring of Advanced Nasopharyngeal Cancer

Hematology/oncology clinics of North America, 2008-12, Vol.22 (6), p.1267-1278

2008

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(126)
Mit Volltextzugriff
(122)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(72)
Science & Technology
(72)
Oncology
(50)
Humans
(47)
Female
(23)
Chemotherapy
(21)
Patients
(20)
Male
(19)
Middle Aged
(18)
Cancer Therapies
(17)
Lung Cancer
(16)
Tumors
(15)
Adult
(14)
Aged
(14)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Lung Neoplasms - Drug Therapy
(14)
Mutation
(13)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Antineoplastic Agents - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer

Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas

The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium

Reflecting on COVID-19: The Hong Kong Experience of Flattening the Curve Without Lockdown

Developing Drugs for Sarcomas in a Brave New World

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Primary cardiac sarcomas: A multi‐national retrospective review

Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

Update on the Management and Therapeutic Monitoring of Advanced Nasopharyngeal Cancer

Suchergebnisse filtern